Search - tctmd.com

Displaying 141 - 160 of 171

Sort: Relevancy | Date

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

November 17, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

Acute Hyperglycemia Worsens Post-AMI Prognosis

October 24, 2014

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

Advertisement

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Acute Hyperglycemia Worsens Post-AMI Prognosis

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content